Genetic Technologies Ltd.

11/08/2018 | Press release | Distributed by Public on 11/08/2018 03:12

Change to CEO’s Remuneration


8 November 2018___________________________________________________________________________________

Change to CEO's Remuneration

Melbourne, Australia, 8 November 2018:Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE)wishes to advise changes to the remuneration package of the Company's Chairman and interimCEO, Dr Paul Kasian.

Dr Kasian's executive salary has been updated to align his remuneration more closely with market rates and reflect the time, commitment and effort required to perform the interim CEO role.

In accordance with ASX Listing Rule 3.16.4, the changes toDr Kasian's remuneration package, which will result in an increase of his total remuneration from $ 153,000 p.a. to $ 200,000 p.a. (inclusive of a 9.5% superannuation contribution) are as follows:

  • Chairman and Directors fees: $ 103,772 p.a. unchanged,

  • Salary: $ 49,227 p.a. increasing to $ 96,228 p.a.

All other terms and conditions of Dr Kasian's interim CEO agreement remain unchanged.

The Board has also recently committed to undertake an executive search for a full time CEO.


Dr Lindsay Wakefield

Jason Wong (USA)

Chairman-Remuneration Committee

Blueprint Life Science Group

Genetic Technologies Limited

+1 (415) 375 3340, Ext. 4

+ 61 3 8412 7000

About Genetic Technologies Limited

Genetic Technologies Limited(ASX: GTG; Nasdaq: GENE)is a diversified molecular diagnostics company embracing blockchain technologies across Genomic testing platforms. GTG offers cancer predictive testingand assessment tools to help physicians proactively manage patient health. The Company's lead product,BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. For more information, please

Genetic Technologies is developing a pipeline of risk assessment products including a novel colorectal cancer (CRC) test. For more information, please

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of thePrivate Securities Litigation Reform Act.The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.